OR WAIT null SECS
April 03, 2008
Also, VaxGen and Raven terminate merger agreement, Darren Head appointed CEO of Cytovance, more...
April 02, 2008
The economic case for personalized medicine offers a solution to the industry's recent woes.
A changing regulatory environment is on the horizon for excipient suppliers and users.
Moderate growth is projected for the global excipients market. Excipient producers target blends and new grades for improving functionality and performance.
Financial experts share their insights for the performance for innovator drug companies and generic-drug players.
The FDA itself issues a cry for help. Is anybody listening?
Excipient producers and industry observers share their perspectives on innovation for excipients.
Heparin contamination casts a shadow on regulatory oversight of product quality.
Brief pharmaceutical news items for April 2008.
April 01, 2008
The blood–brain barrier (BBB) forms an interface between the circulating blood and the brain, and functions as a tremendously effective barrier for the delivery of potential neurotherapeutics into the brain parenchyma. Conversely, the BBB possesses various carrier-mediated transport systems for the uptake of small molecules, such as essential nutrients and vitamins. These transporters have become an attractive target for drug/prodrug design in an attempt to ferry drug molecules across the BBB. Central nervous system (CNS) drug delivery is often limited by poor brain penetration of the potential drug candidate. As a result of its unique barrier properties, the BBB poses a huge challenge for the delivery of potential neurotherapeutics into the brain parenchyma.1 It is estimated that only 2% of small-molecule drugs and ,0.1% of novel protein and peptide pharmaceuticals developed for CNS diseases reach therapeutic concentrations in the brain.2,3 Many of the pharmacologically active drugs tend to fail..